MA41432A - Composition pharmaceutique pour le traitement de maladies gastro-intestinales - Google Patents
Composition pharmaceutique pour le traitement de maladies gastro-intestinalesInfo
- Publication number
- MA41432A MA41432A MA041432A MA41432A MA41432A MA 41432 A MA41432 A MA 41432A MA 041432 A MA041432 A MA 041432A MA 41432 A MA41432 A MA 41432A MA 41432 A MA41432 A MA 41432A
- Authority
- MA
- Morocco
- Prior art keywords
- treatment
- pharmaceutical composition
- gastrointestinal diseases
- gastrointestinal
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/245—Bismuth; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20150015339 | 2015-01-30 | ||
KR1020150147513A KR101583452B1 (ko) | 2015-01-30 | 2015-10-22 | 위장질환 치료용 의약 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA41432A true MA41432A (fr) | 2017-12-05 |
Family
ID=55169799
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA041432A MA41432A (fr) | 2015-01-30 | 2016-01-27 | Composition pharmaceutique pour le traitement de maladies gastro-intestinales |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP3250199A4 (ru) |
JP (1) | JP6419347B2 (ru) |
KR (2) | KR101583452B1 (ru) |
CN (1) | CN107205947B (ru) |
AR (1) | AR105413A1 (ru) |
CL (1) | CL2017001680A1 (ru) |
CO (1) | CO2017006222A2 (ru) |
EA (1) | EA032385B9 (ru) |
EC (1) | ECSP17038599A (ru) |
GE (1) | GEP20196941B (ru) |
MA (1) | MA41432A (ru) |
MX (1) | MX2017007567A (ru) |
MY (1) | MY195824A (ru) |
PE (1) | PE20171340A1 (ru) |
PH (1) | PH12017550051A1 (ru) |
SA (1) | SA517382016B1 (ru) |
TW (1) | TWI635859B (ru) |
UA (1) | UA116517C2 (ru) |
WO (1) | WO2016122226A2 (ru) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101988479B1 (ko) | 2017-10-11 | 2019-09-24 | (주)휴럼 | 리트세노라이드를 유효성분으로 하는 헬리코박터 파이로리 균주로부터 유래되는 위장질환 예방 및 치료용 약학 조성물 |
KR102286499B1 (ko) * | 2018-04-13 | 2021-08-05 | 주식회사 삼양홀딩스 | 레날리도마이드를 포함하는 약제학적 조성물 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE81011T1 (de) * | 1987-03-09 | 1992-10-15 | Procter & Gamble | Zusammensetzungen und ihre verwendung zur behandlung von magen-darmstoerungen. |
US4990610A (en) * | 1988-08-25 | 1991-02-05 | Applied Analytical Industries, Inc. | Method for preparing high potency sucralfate |
EP0403048A3 (en) * | 1989-06-14 | 1991-01-30 | Warner-Lambert Company | Medicated compositions containing sucralfate and processes for their production |
KR970006083B1 (ko) * | 1992-01-22 | 1997-04-23 | 주식회사 대웅제약 | 위장질환 치료용 의약 조성물 |
ES2173183T3 (es) * | 1994-04-26 | 2002-10-16 | Chugai Pharmaceutical Co Ltd | Procedimiento de preparacion de sucralfato granulado y fundido. |
JPH0879097A (ja) * | 1994-09-01 | 1996-03-22 | Matsushita Electric Ind Co Ltd | 携帯無線機 |
KR970006083A (ko) | 1995-07-06 | 1997-02-19 | 한승준 | 자동차용 카울부의 와이어 고정장치 취부구조 |
AU8354498A (en) * | 1997-08-25 | 1999-03-16 | Procter & Gamble Company, The | Combined preparations for treating upper gastrointestinal tract distress |
WO2000078307A1 (en) * | 1999-06-21 | 2000-12-28 | Daewoong Pharmaceutical Co., Ltd. | Orally administrable pharmaceutical preparation having therapeutic effect on gastrointestinal disorders comprising coated ranitidine, bismuth subcitrate and sucralfate |
JP2006076956A (ja) * | 2004-09-10 | 2006-03-23 | Taiyo Yakuhin Kogyo Kk | 胃炎の治療・予防用配合剤 |
KR101617054B1 (ko) * | 2008-07-01 | 2016-04-29 | 라이온 가부시키가이샤 | 고형내복제제 |
KR20110105223A (ko) * | 2010-03-18 | 2011-09-26 | 일양약품주식회사 | 일라프라졸 및 수크랄페이트와 비스무스 제제의 혼합물을 함유하는 위장질환을 예방 또는 치료하기 위한 경구용 약제 조성물 |
KR20140072673A (ko) * | 2012-12-05 | 2014-06-13 | (주)한국파비스제약 | 경구용 위장질환 치료를 위한 정제 |
-
2015
- 2015-10-22 KR KR1020150147513A patent/KR101583452B1/ko active IP Right Review Request
- 2015-12-31 KR KR1020150190850A patent/KR20160094268A/ko active Application Filing
-
2016
- 2016-01-27 TW TW105102582A patent/TWI635859B/zh active
- 2016-01-27 MA MA041432A patent/MA41432A/fr unknown
- 2016-01-28 PE PE2017001147A patent/PE20171340A1/es unknown
- 2016-01-28 MX MX2017007567A patent/MX2017007567A/es active IP Right Grant
- 2016-01-28 GE GEAP201614551A patent/GEP20196941B/en unknown
- 2016-01-28 WO PCT/KR2016/000935 patent/WO2016122226A2/en active Application Filing
- 2016-01-28 UA UAA201707833A patent/UA116517C2/uk unknown
- 2016-01-28 MY MYPI2017702737A patent/MY195824A/en unknown
- 2016-01-28 EP EP16743704.5A patent/EP3250199A4/en not_active Withdrawn
- 2016-01-28 CN CN201680007680.7A patent/CN107205947B/zh active Active
- 2016-01-28 EA EA201791458A patent/EA032385B9/ru not_active IP Right Cessation
- 2016-01-28 JP JP2017540683A patent/JP6419347B2/ja active Active
- 2016-01-29 AR ARP160100272A patent/AR105413A1/es unknown
-
2017
- 2017-06-20 EC ECIEPI201738599A patent/ECSP17038599A/es unknown
- 2017-06-23 CO CONC2017/0006222A patent/CO2017006222A2/es unknown
- 2017-06-23 CL CL2017001680A patent/CL2017001680A1/es unknown
- 2017-07-25 PH PH12017550051A patent/PH12017550051A1/en unknown
- 2017-07-29 SA SA517382016A patent/SA517382016B1/ar unknown
Also Published As
Publication number | Publication date |
---|---|
BR112017013857A2 (pt) | 2018-02-27 |
EA032385B1 (ru) | 2019-05-31 |
MY195824A (en) | 2023-02-22 |
EA032385B9 (ru) | 2019-07-31 |
CL2017001680A1 (es) | 2018-01-12 |
KR101583452B1 (ko) | 2016-01-11 |
WO2016122226A2 (en) | 2016-08-04 |
CN107205947B (zh) | 2020-05-22 |
JP2018503672A (ja) | 2018-02-08 |
SA517382016B1 (ar) | 2021-03-18 |
CO2017006222A2 (es) | 2017-09-20 |
MX2017007567A (es) | 2017-10-19 |
KR101583452B9 (ko) | 2022-05-02 |
WO2016122226A3 (en) | 2016-09-15 |
PH12017550051A1 (en) | 2018-01-29 |
PE20171340A1 (es) | 2017-09-13 |
AR105413A1 (es) | 2017-10-04 |
TW201639559A (zh) | 2016-11-16 |
ECSP17038599A (es) | 2017-09-29 |
KR20160094268A (ko) | 2016-08-09 |
TWI635859B (zh) | 2018-09-21 |
UA116517C2 (uk) | 2018-03-26 |
EP3250199A2 (en) | 2017-12-06 |
CN107205947A (zh) | 2017-09-26 |
JP6419347B2 (ja) | 2018-11-07 |
GEP20196941B (en) | 2019-01-10 |
EA201791458A1 (ru) | 2017-11-30 |
EP3250199A4 (en) | 2018-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA45481A (fr) | Utilisation d'exosomes pour le traitement de maladies | |
MA51200A (fr) | Nouveaux composés et compositions pharmaceutiques associées pour le traitement de maladies | |
MA49767A (fr) | Conjugués de cytokine pour le traitement de maladies auto-immunes | |
MA47719A (fr) | Esketamine pour le traitement de la dépression | |
MA49144A (fr) | Polythérapies pour le traitement du cancer | |
MA55629A (fr) | Compositions d'anticorps pour le traitement de tumeurs | |
IL255509B (en) | Compounds as modulators of ccr2, pharmaceutical preparations containing them and their use in the treatment of diseases | |
MA41449A (fr) | Polythérapies pour le traitement de cancers | |
MA39748A (fr) | Cenicriviroc pour le traitement de la fibrose | |
MA44875A (fr) | Compositions pour le traitement de troubles acido-basiques | |
MA50409A (fr) | Polythérapies pour le traitement du cancer | |
PL3785733T3 (pl) | Kompozycja farmaceutyczna do leczenia autyzmu | |
MA48637A (fr) | Polythérapies pour le traitement du cancer | |
FR3032353B1 (fr) | Composition pharmaceutique et dispositif pour le traitement de la douleur | |
MA53568A (fr) | Médicaments pour le traitement de maladies ophtalmiques | |
MA42999A (fr) | Polythérapie pour le traitement de malignités | |
MA42953A (fr) | Composés et compositions pour le traitement de troubles oculaires | |
MA42930A (fr) | Traitement de maladies neurodégénératives | |
MA46086A (fr) | Schéma posologique pour le traitement de tumeurs solides | |
MA43800A (fr) | Octréotide par voie orale pour le traitement de maladies | |
FR3017298B1 (fr) | Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires | |
GB201618424D0 (en) | Treatment of antibody mediated disease | |
MA39927A (fr) | Inhibiteurs de glyt1 pour le traitement de troubles hématologiques | |
MA39950A (fr) | Dérivé de 2-acylaminothiazole pour le traitement des maladies des voies urinaires et de la vessie | |
FR3022139B1 (fr) | Nouvelles compositions pour le traitement des rougeurs cutanees et de la rosacee |